These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 28281738)

  • 21. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
    Xie J; Jiang M; Lin Y; Deng H; Li L
    Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial.
    Erol T; Tekin A; Katırcıbaşı MT; Sezgin N; Bilgi M; Tekin G; Zümrütdal A; Sezgin AT; Müderrisoğlu H
    Int J Cardiol; 2013 Aug; 167(4):1396-9. PubMed ID: 22572633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.
    Li WH; Li DY; Qian WH; Liu JL; Xu TD; Zhu H; He HY
    Int Urol Nephrol; 2014 Apr; 46(4):781-6. PubMed ID: 24570327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
    Barbieri L; Verdoia M; Suryapranata H; De Luca G;
    Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous Fluid Therapy Is Associated with a Reduced Incidence of Contrast-Induced Nephropathy but not with a Reduced Long-Term Incidence of Renal Dysfunction After Cardiac Catheterization.
    Bottinor W; Chawla R; Danyi P; Patel K; Turlington J; Sangal K; Hong W; Perera RA; Jovin IS
    Cardiovasc Revasc Med; 2020 Jan; 21(1):20-23. PubMed ID: 31378387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial.
    Vasheghani-Farahani A; Sadigh G; Kassaian SE; Khatami SM; Fotouhi A; Razavi SA; Mansournia MA; Yamini-Sharif A; Amirzadegan A; Salarifar M; Sadeghian S; Davoodi G; Borumand MA; Esfehani FA; Darabian S
    Am J Kidney Dis; 2009 Oct; 54(4):610-8. PubMed ID: 19619921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures.
    Feldkamp T; Luedemann M; Spehlmann ME; Freitag-Wolf S; Gaensbacher J; Schulte K; Bajrovic A; Hinzmann D; Hippe HJ; Kunzendorf U; Frey N; Luedde M
    Clin Res Cardiol; 2018 Feb; 107(2):148-157. PubMed ID: 28939956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remote ischemic preconditioning reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography/intervention: Systematic review and meta-analysis of randomized controlled trials.
    Pranata R; Tondas AE; Vania R; Toruan MPL; Lukito AA; Siswanto BB
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1200-1212. PubMed ID: 31912996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization.
    Watanabe M; Saito Y; Aonuma K; Hirayama A; Tamaki N; Tsutsui H; Murohara T; Ogawa H; Akasaka T; Yoshimura M; Sato A; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K;
    J Cardiol; 2016 Nov; 68(5):412-418. PubMed ID: 26708123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVert™ plus contrast reduction system.
    Gurm HS; Mavromatis K; Bertolet B; Kereiakes DJ; Amin AP; Shah AP; Hanzel GS; Rao S; Thomas JL; Kumar G
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1228-1235. PubMed ID: 30393942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Random forest for prediction of contrast-induced nephropathy following coronary angiography.
    Liu Y; Chen S; Ye J; Xian Y; Wang X; Xuan J; Tan N; Li Q; Chen J; Ni Z
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):983-991. PubMed ID: 32285318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.